Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-acting drug delivery of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
The current price of ADOIF is $8.87 USD — it has increased by +0% in the past 24 hours. Watch Adocia SA stock price performance more closely on the chart.
What is Adocia SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adocia SA stocks are traded under the ticker ADOIF.
What is Adocia SA market cap?▼
Today Adocia SA has the market capitalization of 75.87M
What were Adocia SA earnings last quarter?▼
ADOIF earnings for the last quarter are -0.9 USD per share, whereas the estimation was 0 USD resulting in a -∞% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adocia SA revenue for the last year?▼
Adocia SA revenue for the last year amounts to 12.1M USD.